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PREDICTION OF ACUTE GVHD FOLLOWING NONMYELOABLATIVE CON-
DITIONINGBYMEASUREMENTOF TUMORNECROSIS FACTOR-RECEPTOR
1 (TNFR1) AT BASELINE AND AT DAY 7 AFTER TRANSPLANTATION
Humblet-Baron, S., Willems, E., Dengis, O., Seidel, L., Beguin, Y.,
Baron, F. University of Liege, Belgium
Acute graft-versus-host disease (GVHD) has remained a signifi-
cant cause of nonrelapse mortality after allogeneic hematopoietic
cell transplantation (HCT) with nonmyeloablative conditioning.
The role of tumor necrosis factor-alpha (TNF-a) in the biology
of acute GVHD following nonmyeloablative conditioning has not
been studied thus far. Here, we measured TNF receptor 1
(TNFR1) as a surrogate marker for TNF-a in 106 patients before
the start of the conditioning regimen (baseline) and 7 days after al-
logeneic HCT following nonmyeloablative conditioning. The non-
myeloablative regimen consisted of 2 Gy total body irradiation
(TBI) alone (n5 15), 2 Gy TBI plus fludarabine 90 mg/m2
(n5 73), or 4 Gy TBI plus fludarabine 90 mg/m2 (n5 18).
TNFR1 levels increased significantly from baseline to day 7 after
nonmyeloablative HCT (P\0.0001). Patients conditioned with
4 Gy TBI had higher TNFR1 day 7/baseline ratio than those con-
ditioned with 2 Gy TBI (median 1.65 versus 1.25; P5 0.01). Pa-
tients with grade II-IV acute GVHD had higher relative (defined
as TNFR1 level divided by baseline TNFR1 level) TNFR1 levels
than those without grade II-IV acute GVHD on day 7 (NS), and
on day 35 after HCT (P5 0.04), but not on day 63 after HCT.
In a multivariate Cox model, high TNFR1 day7/baseline ratio
was associated with grade II-IV (HR5 2.2, P5 0.01) and grade
III-IV (HR5 2.9, P5 0.007) acute GVHD, but had no impact
on overall survival (P5 0.8). In summary, our data suggest that
nonmyeloablative conditioning induce the generation of TNF-a,
and that the magnitude of TNF-a generation depends on the con-
ditioning intensity (2 Gy versus 4 Gy TBI). Further, assessment of
TNFR1 levels before and on day 7 after nonmyeloablative HCT
provided useful information on subsequent risk of experiencing
acute GVHD.398
CD103 DEFICIENCY SEPARATES GRAFT-VERSUS-HOST DISEASE AND
GRAFT-VERSUS-LEUKEMIA EFFECTS MEDIATED BY DONOR CD8 T CELLS
Hamadani, M.1, Liu, K.2, Anthony, B.A.3, Gaughan, A.3, Wang, J.-J.3,
Shana’ah, A.4, Byrd, J.C.5, Devine, S.M.5, Johnson, A.J.5, Hadley, G.A.3
1Mary Babb Randolph Cancer Center, West Virginia University, Mor-
gantown, WV; 2University of Maryland Medical School, Baltimore,
MD; 3The Ohio State University, Columbus, OH; 4The Ohio State Uni-
versity, Columbus, OH; 5The Ohio State University, Columbus, OH
We have previously shown that CD103, an integrin conferring
specificity for the epithelial ligand E-cadherin, is required for donor
CD8 mediated intestinal GVHD. Owing to the lack of E-cadherin
expression on hematopoietic cells, we hypothesized that CD103 de-
ficiency would attenuate GVHD, while sparing GVL effects.
Methods:To examine the role of CD103 in CD8mediatedGVHD,
lethally irradiated A/J hosts (H-2a) were reconstituted by 1.0  107
BALB/c (H-2d), bone marrow cells (BMCs) and 1.0  107 alloanti-
gen-primed CD8 T cells from either WT or CD103-/- mice. To
test whether CD103 deficiency compromises GVL effects mediated
by donorT cells, 2.0 107 splenocytes fromCD103-/- orWTBalb/
c (H-2d) mice were co transferred into BALB.scid (H-2d) recipients,
together with 1.0 107 splenocytes from a Em-TCL1 mouse (H-2b)
with end-stage chronic lymphocytic leukemia (CLL). A control
group received CLL cells alone. T cells from the Em-TCL1 spleno-
cytes were depleted to prevent alloreactivity against BALB.scid
recipients.
Results:Upon adoptive transfer into A/J recipient mice, primed
WT CD8 T cells elicited severe GVHD resulting in 75%
GVHD mortality. In contrast, CD103-/- CD8 T cells elicited
mild or undetectable GVHD (23% GVHD mortality). At au-
topsy compared to the CD103-/- recipients, WT CD8 recipi-
ents exhibited severe lesions in the intestinal and hepatic
epithelium. These data demonstrate that CD103 expression is
required for GVHD pathogenesis mediated by primed CD8 T
cells in this model. To assess the role of CD103 in effectorT cell mediated GVL effects, splenocytes from either WT or
CD103-/- BALB/c mice were adoptively transferred in BALB.s-
cid mice along with CLL cells from Em-TCL1. A control group
of BALB.scid mice received CLL cells only. FACS analyses of
peripheral blood revealed development of CLL in BALB-scid
mice receiving only CLL cells as early as day +14 post cell
transfer. In contrast no CLL was detected in peripheral blood
of mice receiving WT or CD103-/- splenocytes at any time
point. BALB.scid mice receiving CLL cells only, displayed
poor grooming, decreased activity, dyspnea and massive heptos-
plenomegaly. Mean survival time of BALB.scid mice in CLL
only group was 73 days. In contrast all the mice receiving
WT or CD103-/- cells survived beyond day +110 with no evi-
dence of CLL (p-value5 0.0001).
Conclusion:Our data demonstrate that CD103 deficiency atten-
uates GVHD while sparing GVL effects and thus hold great
translational potential.
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HUMAN T CELL RAPAMYCIN RESISTANCE AND TH1/TC1 POLARIZATION
AUGMENT XENOGENEIC GRAFT-VERSUS-HOST DISEASE
Amarnath, S.1, Mangus, C.W.1, Costanzo, C.M.1, Foley, J.E.1,
Eckhaus, M.2, Levine, B.L.3, June, C.H.3, Fowler, D.H.1 1National Can-
cer Institute, National Institutes of Health, Bethesda, MD; 2National In-
stitutes of Health, Bethesda, MD; 3University of Pennsylvania,
Philadelphia, PA
Adoptive transfer of co-stimulated T cells represents an immu-
notherapeutic method currently under clinical investigation. We
hypothesized that the ex vivo acquisition of rapamycin resistance
and type I cytokine polarization during co-stimulation would
augment the in vivo effect of adoptively transferred human T
cells. In the presence of rapamycin, T cell co-stimulation and
polarization with IL-12 or IFN-g permitted human CD4+ and
CD8 +T cell differentiation towards a Th1/Tc1 phenotype: by
intracellular flow, median percentage expression of Foxp3, IFN-
g, and T-bet was 4%, 20%, and 72%, respectively. Phospho-
flow cytometry revealed that such Th1/Tc1 cells expressed
activated STAT1 and STAT4 in spite of mTOR blockade;
STAT activation was abrogated by PI3 kinase inhibition. Rapa-
mycin-resistant human Th1/Tc1 cells (Th1/Tc1.R cells): (1)
had increased expression of the autophagy-related gene LC3BII
by gene array and protein analysis; (2) preferentially expressed
anti-apoptotic bcl-2 family members (reduced Bax, Bak; increased
phospho-Bad); (3) maintained mitochondrial membrane poten-
tials; and (4) had reduced apoptosis relative to control Th1/
Tc1 cells not generated in rapamycin (p5 0.04). The anti-apo-
ptotic phenotype of Th1/Tc1.R cells was abrogated by co-incu-
bation with the autophagy inhibitor, 3-methyl adenine. The in
vivo effect of the Th1/Tc1.R cells was evaluated using two xeno-
geneic GVHD (x-GVHD) models. First, in an LPS-induced
x-GVHD model, Th1/Tc1.R cells resulted in lethality in 75%
recipients; soluble TNF-a receptor therapy with etanercept re-
duced the frequency of lethality to 15%. Second, using a non-
LPS natural history model of x-GVHD, recipients of Th1/
Tc1.R cells (relative to recipients of control Th1/Tc1 cells)
had increased human T cell engraftment (day 30 post-BMT,
p5 0.001), increased human T cell cytokine levels, increased hu-
man T cell expression of the cytotoxic degranulation molecule
CD107 (p5 0.05), and increased human T cell infiltration of
skin, gut, and liver. In this model, lethality due to x-GVHD
was also increased in Th1/Tc1.R cell recipients (lethality in-
creased from 20% to 70%, p5 0.04). We conclude that rapamy-
cin therefore does not impair human T cell capacity for type I
differentiation. Rather, by promoting autophagy rapamycin per-
mits stable expression of T-bet and generates an anti-apoptotic
Th1/Tc1 effector phenotype, thereby yielding increased
x-GVHD.400
B- CELL DEPLETION AS THERAPY FOR STEROID REFRACTORY CHRONIC
GVHD IS MOST EFFECTIVE FOR SCLEROSIS OF THE SKIN
Dorp, S., Boome, L.C.J., Lokhorst, H.M., Petersen, E.J.,
Minnema, M.C., Span, B.L.F.R., Ebeling, E.S., Canninga, M.R.,
Meijer, E., Kuball, J. UMCU, Utrecht, Netherlands; UMCU, Utrecht,
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Rotterdam, South-Holland, Netherlands; UMCU, Utrecht, Netherlands
Introduction: Chronic graft-versus-host disease (cGVHD) is the
major long term complication of allogeneic stem cell transplantation
and shares similarities with auto-immune diseases, like systemic scle-
rosis. Although the contribution of donorT-cells in the development
of both acute and chronicGVHD is beyond doubt; the role of B-cells
is less defined. Two observations suggest that B-cells do contribute
to cGVHD; autoantibodies can be detected in 15-90% of patients
and several small-scale retrospective clinical studies demonstrated
that in vivo depletion of B-cells with the CD20-specific Ab rituximab
results in amelioration of cGVHD symptoms in heavily pretreated
steroid-refractory patients.
Objective: In order to prospectively investigate B-cell depletion as
therapy for cGVHD, we have studied the efficacy of the rituximab
in patients with steroid-refractory extensive cGVHD.
Methods: In an ongoing prospective phase I/II study 15 patients
were treated with rituximab (375 mg/m2 per week for 4 consecutive
weeks). Clinical responses were monitored monthly for 1 year ac-
cording to the NIH criteria.
Results: A total of 60 infusions were administered to 15 patients.
The clinical responses were so far analyzed in 12 patients. Median
follow-up 6.5 months (range 1-13). Eight patients showed a partial
response (67%) of which 42% had an ongoing response up to 1
year of follow-up and 25% relapsed. Two relapsed patients were
retreated 8 months after cessation of the initial treatment and
showed again a partial response. In patients with deep sclerosis
(n5 10), sclerotic features disappeared completely or partially in
80%. In patients with involvement of eyes (n5 10), mucosa
(n5 4) and gastro-intestinal tract (n5 4) response was observed
in 50%, 25% and 25%. Consequently, prednisone dosage could
be reduced in 58% and in 33% of the patients prednisone treat-
ment was stopped.
Conclusion: Rituximab treatment is a feasible and effective treat-
ment in patients with steroid refractory cGVHD. In addition, also
patients with relapse of cGVHD after cessation of rituximab treat-
ment can be successfully treated. Thereby, sclerotic lesions of the
skin improved in the majority of patients whereas eye, mucosal and
gastro-intestinal tract involvement was less reversible. We speculate
that the lack of improvement of eye and mucosal involvement is
a consequence of an early and irreversible destruction of lacrimal
and salivary glands and this argues for an upfront application of
rituximab in cGVHD.401
ORAL HUMAN RECOMBINANT LACTOFERRIN PREVENTS ACUTE GRAFT-
VERSUS-HOST DISEASE AND STIMULATES RECONSTITUTION OF DONOR
BONE MARROW-DERIVED T-CELLS IN A MOUSE MODEL OF BONE MAR-
ROW TRANSPLANTATION
Akhtari, M., Hossain, S.M., Forghani, P., Waller, E.K. Winship Cancer
Institute, Emory University School of Medicine, Atlanta, GA; Winship
Cancer Institute, Emory University School of Medicine, Atlanta, GA;
Winship Cancer Institute, Emory University School of Medicine, Atlanta,
GA; Winship Cancer Institute, Emory University School of Medicine,
Atlanta, GA
Background: Lactoferrin, an iron-binding protein with multiple
physiological functions (anti-microbial, anti-inflammatory, and im-
munomodulatory), is a component of mammalian milk. Lactoferrin
has immune modulatory effects through interaction with natural
killer cells, T-cells and interfering with cytokine production. There
is in vitro evidence that lactoferrin can reduce lipopolysaccaride-in-
duced release or pro-inflammatory cytokines in mice and human
possibly through scavenging lipopolysaccaride (LPS) in the intesti-
nal lumen. The central hypothesis of this research project was that
administration of human recombinant lactoferrin (hrLF) tomice un-
dergoing allogeneic bone marrow transplantation (allo BMT) will
reduce the pro-inflammatory effects of the conditioning regimens,
and gut epithelial tissue damage, resulting in less non-specific activa-
tion of donor T-cells that cause GvHD.Methods: Irradiated (11 Gy) C57BL/6 recipient received 5106 T
cell depleted (TCD) bone marrow cells and 3106 plastic non-ad-
herent splenocytes from naı¨ve BA.B10 congenic donors. To test the
hypothesis we studied the effect of oral hrLF administration on
GvHD in murine models of allo BMT. Lactoferrin (hrLF)
(75 mg/mouse) or PBS was administered by gastric gavage from
day -4 for up to 30 days in surviving recipients. GvHD was mon-
itored clinically by using criteria such as weight reduction and di-
arrhea. Survival was assessed. Flow cytometry was used to
determine donor chimerism, immune reconstitution and the fre-
quency of naive CD62L+ T cells.
Results: Oral hrLF reduced acute GvHD and the experimental
group survived 100%; however, 67% of the control group survived.
There was a significant difference in the number of peripheral blood
nucleated cells (PBNC) and bone marrow nucleated cells (BMNC)
between the experimental and control groups (p5 0.02 and
p5 0.01). No significant difference in bone marrow CD4+ and
CD8+ T-cells, andCD4+CD62L+T-cells from donor spleen derived
cells between two groups was found.
Conclusion: Oral hrLF treatment successfully controlled GvHD
and suppressed donor T-cells. There were significant differences
between lactoferrin group and the control mice including diar-
rhea, weight loss, and numbers of nucleated cells. Hence, prophy-
lactic use of lactoferrin is a novel therapeutic approach for
prophylaxis of GvHD in patients undergoing allogeneic
HSCT.402
INDUCTION OF PROSTATE-SPECIFIC T CELLS AND GRAFT-VERSUS-
TUMOR EFFECT IN PATIENTS WITH ADVANCED PROSTATE CANCER
AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Mattsson, J.1, Gertow, J.2, Henningsohn, L.3, Gustavsson, O.3,
Uhlin, M.2 1Centre for Allogeneic Stem Cell Transplantation, Stockholm,
Sweden; 2Clinical Immunology, Stockholm, Sweden; 3Clintec, Stockholm,
Sweden
Therapies for localized prostate cancer include curative surgery
and radiotherapy while treatment for metastatic disease is palliative
and based on depriving the tumor cells of their androgen stimulation
that reduces tumor growth rate. Therefore, we started to investigate
the potential of allogeneic SCT as a treatment for non-curable pros-
tate cancer.
Two patients underwent allogeneic SCT with PBSC from HLA-
identical sisters after a non-myeloablative conditioning regimen as
treatment for metastatic prostate adenocarcinoma. Frequencies of
prostate-specific T cells in the peripheral blood of the patients, sib-
ling donors and a group of control individuals were determined by
flow cytometry using tetrameric and pentameric HLA A2 com-
plexes containing peptides derived from the prostate specific anti-
gen (PSA). Cytotoxic activity of PSA-peptide-specific T-cells
against peptide-pulsed target cells was analyzed ex vivo by 51Cr-re-
lease assays.
Stable clinical and laboratory remission lasting for more than 4
years was observed after SCT for the first transplanted patient.
The patient is now 6.5 years after SCT but now slowly increasing
in PSA indiacting tumor progression. The PSA level is today 12
ng/mL. The second patient has decreased in PSA from 257 ng/mL
before SCT to 70 ng/mL and without clinical signs of progression
one year after SCT. Both patients are doing clinically excellent
and have a good quality of life. In the second patient a dramatic in-
crease was detected in PSA levels during development of GVHD.
After treatment of GVHD the PSA levels decreased continuously.
We believe that the sudden increase of PSA was due to an antitumor
attack of prostate-specific T cells indicating a graft-versus-tumor ef-
fect. Using HLA containing pentamers with PSA-derived peptides
we could detect prostate-specific CD8+ T cells in both patients in
high frequencies over several months. Furthermore, higher frequen-
cies of PSA-specific T-cells were revealed in the peripheral blood of
the patients and female controls as compared with male healthy
controls.
Our data suggest that allogeneic SCT led to the generation of a T
cell mediated prostate-specific immunity in both patients. The in vi-
tro and ex vivo immunological monitoring performed indicate an
